Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure

(MedPage Today) -- CHICAGO--A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial.
Incident...